Skye Bioscience, Inc. Research and Development in Process
Skye Bioscience, Inc. (SKYE) reported Research and Development in Process of $21.22 million for the 3-month period ending 2023-09-30, per its 10-Q filed 2023-11-14.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentInProcess · last filed 2023-11-14
- Skye Bioscience, Inc. research and development in process for the quarter ending 2023-09-30 was $21.22M.
- Skye Bioscience, Inc. research and development in process for the quarter ending 2022-09-30 was $0.00.
| Period end | Research and Development in Process 3 month | Research and Development in Process 9 month |
|---|---|---|
| 2023-09-30 | $21.22M 10-Q · filed 2023-11-14 | $21.22M 10-Q · filed 2023-11-14 |
| 2022-09-30 | $0.00 10-Q · filed 2023-11-14 | $0.00 10-Q · filed 2023-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CalciMedica, Inc. (CALC) | United States | $0.061B | -1.42 |
| TALPHERA, INC. (TLPH) | United States | $0.060B | |
| Boundless Bio, Inc. (BOLD) | United States | $0.059B | -0.88 |
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| Rein Therapeutics, Inc. (RNTX) | United States | $0.063B | -1.76 |
| HYPERION DEFI, INC. (HYPD) | United States | $0.065B | |
| Annovis Bio, Inc. (ANVS) | United States | $0.056B | -1.58 |
| XBiotech Inc. (XBIT) | United States | $0.066B | -1.56 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |